Schizophrenia – Landscape & Forecast – Disease Landscape And Forecast G7

The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also available. Competition is also intensifying among antipsychotic long-acting injectables (LAIs) as new therapies launch, offering largely incremental advantages over treatment mainstays. Indeed, late-phase emerging therapies—including new oral atypical antipsychotics (Alkermes’s ALKS 3831, Acadia Pharmaceuticals’ pimavanserin), new LAIs (e.g., Janssen’s paliperidone six-month depot, Teva’s TV-46000), and others (Sunovion / Sumitomo Dainippon Pharma’s SEP-363856, BioXcel’s BXCL501)—must be clearly differentiated from established therapies to gain a foothold in this market. The potential of early- to mid-phase therapies to treat the negative symptoms and cognitive impairment associated with schizophrenia (CIAS)—symptom domains on which drug developers are increasingly focusing—remains to be seen; few agents have promising results in mid-phase clinical studies (e.g., Boehringer Ingelheim’s BI 425809 in CIAS).

Questions Answered

  • What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
  • What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?
  • What are the biggest areas of unmet need? Which late-phase therapies have potential to fulfill these needs?
  • What would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? How will these agents be placed in the schizophrenia treatment algorithm?

Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Geographies: United States, EU5, Japan.

Primary research: 29 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.

Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2029, segmented by brands / generics.

Emerging therapies: Phase III / PR: 10 drugs. Coverage of select Phase II and Phase I products.

Table of contents

  • Schizophrenia - Landscape & Forecast - Disease Landscape And Forecast G7
    • Key Updates
      • Q3 2021
        • September 2021
        • July 2021
      • Q2 2021
        • May 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • November 2020
    • Key Findings
      • Schizophrenia - Key Findings - September 2021
        • November 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Schizophrenia: 2020
        • Market Share of Drug Classes for Schizophrenia: 2030
        • Schizophrenia SWOT Analysis
      • COVID-19: Market Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Schizophrenia?
          • What Factors Are Constraining the Market for Schizophrenia?
          • Market Share and Share of Treated Patients for Schizophrenia by Region: 2020 and 2030
          • Major-Market Sales in Schizophrenia by Drug Class: 2020-2030
          • Major-Market Patient Share by Drug Class and Drug-Treated Patients in Schizophrenia: 2020-2030
          • Major-Market Brand and Generic Sales in Schizophrenia: 2020-2030
          • Major-Market Brand and Generic Patient Share in Schizophrenia: 2020-2030
        • Drug-Class-Specific Trends
          • Major-Market Sales of Key Oral Atypical Antipsychotics in Schizophrenia: 2020-2030
          • Patient Share of Key Oral Atypical Antipsychotics for Schizophrenia in the United States: 2020-2030
          • Patient Share of Key Oral Atypical Antipsychotics for Schizophrenia in the EU5: 2020-2030
          • Patient Share of Key Oral Atypical Antipsychotics for Schizophrenia in Japan: 2020-2030
          • Major-Market Sales of LAIs of Key Atypical Antipsychotics in Schizophrenia: 2020-2030
          • Patient Share of LAIs of Atypical Antipsychotics for Schizophrenia in the United States: 2020-2030
          • Patient Share of LAIs of Atypical Antipsychotics for Schizophrenia in the EU5: 2020-2030
          • Patient Share of LAIs of Atypical Antipsychotics for Schizophrenia in Japan: 2020-2030
          • Sales of Ulotaront (SEP-363856) for Schizophrenia by Country: 2020-2030
          • Patient Share of Ulotaront (SEP-363856) for Schizophrenia by Country: 2020-2030
          • Sales of BXCL501 in Schizophrenia by Region: 2020-2030
          • Patient Share of BXCL501 in Schizophrenia by Region: 2020-2030
          • Sales of KarXT in Schizophrenia by Region: 2020-2030
          • Patient Share of KarXT in Schizophrenia by Region: 2020-2030
          • Sales of BI 425809 in Schizophrenia by Region: 2020-2030
          • Patient Share of BI 425809 in Schizophrenia by Region: 2020-2030
      • Forecast
        • Market Forecast Assumptions - Schizophrenia (2020-2030) - September 2021
        • Market Forecast Dashboard - Schizophrenia (2020-2030) - September 2021
      • Etiology and Pathophysiology
        • Disease Overview
          • Genetic Factors
            • Environmental Factors
              • Environmental Risk Factors
            • Key Pathways and Drug Targets
              • Abnormalities in Brain Structure and Function
              • Epidemiology
                • Key Findings
                  • Epidemiology Populations
                    • Disease Definition
                    • Methods
                    • Sources Used for Lifetime Prevalence Estimates of Schizophrenia
                    • Diagnosed Lifetime Prevalent Cases of Schizophrenia: 2020-2030 (Thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Symptom Status of Schizophrenia
                    • Positive Symptom Cases of Schizophrenia: 2020-2030 (Thousands)
                    • Negative Symptom Cases of Schizophrenia: 2020-2030 (Thousands)
                    • Disease Definition
                    • Methods
                    • Sources Used for Lifetime Prevalence Estimates of Schizophrenia
                    • Diagnosed Lifetime Prevalent Cases with Cognitive Impairment: 2020-2030 (Thousands)
                    • Number of Lifetime Diagnosed and Drug-Treated Prevalent Cases of Schizophrenia in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
                • Current Treatment
                  • Key Findings
                    • Treatment Goals
                      • Key Endpoints Used in Clinical Trials for Schizophrenia
                    • Key Current Therapies
                      • Overview
                      • Mechanism of Action of Key Current Drug Classes Used for Schizophrenia
                      • Current Treatments Used for Schizophrenia
                      • Market Events Impacting the Use of Key Current Therapies for Schizophrenia
                      • Timeline of Launches of Key Branded Atypical Antipsychotics for Schizophrenia in the United States
                      • Atypical Antipsychotics
                      • Impact of Receptor-Binding on Efficacy / Safety Profile of Select Atypical Antipsychotics
                      • Advantages and Disadvantages of Oral Aripiprazole
                      • Advantages and Disadvantages of Aripiprazole One-Month Depot
                      • Expert Insight: Aripiprazole
                      • Advantages and Disadvantages of Aripiprazole Lauroxil
                      • Expert Insight: Aripiprazole Lauroxil
                      • Advantages and Disadvantages of Oral Asenapine
                      • Advantages and Disadvantages of Asenapine Transdermal Patch
                      • Expert Insight: Asenapine
                      • Advantages and Disadvantages of Oral Blonanserin
                      • Advantages and Disadvantages of Blonanserin Transdermal Patch
                      • Advantages and Disadvantages of Brexpiprazole
                      • Ongoing Clinical Development of Brexpiprazole
                      • Expert Insight: Brexpiprazole
                      • Advantages and Disadvantages of Cariprazine
                      • Ongoing Clinical Development of Cariprazine
                      • Expert Insight: Cariprazine
                      • Advantages and Disadvantages of Clozapine
                      • Expert Insight: Clozapine
                      • Advantages and Disadvantages of Iloperidone
                      • Advantages and Disadvantages of Lumateperone
                      • Expert Insight: Lumateperone
                      • Advantages and Disadvantages of Lurasidone
                      • Expert Insight: Lurasidone
                      • Advantages and Disadvantages of Oral Olanzapine
                      • Potential Advantages and Disadvantages of Lybalvi
                      • Advantages and Disadvantages of Olanzapine Pamoate
                      • Expert Insight: Olanzapine
                      • Advantages and Disadvantages of Oral Paliperidone
                      • Advantages and Disadvantages of Paliperidone Palmitate One-Month Depot
                      • Advantages and Disadvantages of Paliperidone Palmitate Three-Month Depot
                      • Expert Insight: Paliperidone
                      • Advantages and Disadvantages of Quetiapine
                      • Expert Insight: Quetiapine
                      • Advantages and Disadvantages of Oral Risperidone
                      • Advantages and Disadvantages of Risperidone Microspheres: Risperdal Consta
                      • Advantages and Disadvantages of Risperidone One-Month Depot: Perseris
                      • Expert Insight: Risperidone
                      • Advantages and Disadvantages of Ziprasidone
                      • Advantages and Disadvantages of Typical Antipsychotics
                      • Expert Insight: Typical Antipsychotics
                    • Medical Practice
                      • Overview
                      • Factors Influencing Drug Selection in Schizophrenia
                      • Treatment Decision Tree for Schizophrenia: United States
                      • Treatment Decision Tree for Schizophrenia: Europe
                      • Treatment Decision Tree for Schizophrenia: Japan
                      • Major-Market Treatment Decision Tree for CIAS
                      • Major-Market Treatment Decision Tree for the Side Effects of Antipsychotics in Schizophrenia
                      • Major-Market Treatment Decision Tree for the Comorbid Symptoms of Schizophrenia
                  • Unmet Need Overview
                    • Current and Future Attainment of Unmet Needs in Schizophrenia
                    • Top Unmet Needs in Schizophrenia: Current and Future Attainment
                    • Expert Insight: Unmet Need in Schizophrenia
                  • Emerging Therapies
                    • Key Findings
                      • Key Emerging Therapies
                        • Key Therapies in Development for Schizophrenia
                        • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Schizophrenia
                        • Pimavanserin Profile
                        • Analysis of the Clinical Development Program for Pimavanserin
                        • Expert Insight: Pimavanserin
                        • Expectations for Launch and Sales Opportunity of Pimavanserin in Schizophrenia
                        • Likely Uses of Pimavanserin for the Treatment of Schizophrenia
                        • Aripiprazole Two-Month Depot Profile
                        • Analysis of the Clinical Development Program for Aripiprazole Two-Month Depot
                        • Expert Insight: Aripiprazole Two-Month Depot
                        • Expectations for Launch and Sales Opportunity of Aripiprazole Two-Month Depot in Schizophrenia
                        • Doria Profile
                        • TV-46000 Profile
                        • Rykindo Profile
                        • Analysis of the Clinical Development Program for Extended-Release Forms of Risperidone
                        • Expert Insight: Extended-Release Forms of Risperidone
                        • Expectations for Launch and Sales Opportunity of Extended-Release Forms of Risperidone in Schizophrenia
                        • Likely Uses of Extended-Release Forms of Risperidone for the Treatment of Schizophrenia
                        • Ulotaront (SEP-363856) Profile
                        • Analysis of the Clinical Development Program for Ulotaront (SEP-363856)
                        • Expert Insight: Ulotaront (SEP-363856)
                        • Expectations for Launch and Sales Opportunity of Ulotaront (SEP-363856) in Schizophrenia
                        • Likely Uses of Ulotaront (SEP-363856) for the Treatment of Schizophrenia
                        • BXCL501 Profile
                        • Analysis of the Clinical Development Program for BXCL501
                        • Expert Insight: BXCL501
                        • Expectations for Launch and Sales Opportunity of BXCL501 in Schizophrenia
                        • Likely Uses of BXCL501 for the Treatment of Schizophrenia
                        • Roluperidone Profile
                        • Analysis of the Clinical Development Program for Roluperidone
                        • Expert Insight: Roluperidone
                        • Expectations for Launch and Sales Opportunity of Roluperidone in Schizophrenia
                        • KarXT Profile
                        • Analysis of the Clinical Development Program for KarXT
                        • Expert Insight: KarXT
                        • Expectations for Launch and Sales Opportunity of KarXT in Schizophrenia
                        • Likely Uses of KarXT for the Treatment of Schizophrenia
                        • BI 425809 Profile
                        • Analysis of the Clinical Development Program for BI 425809
                        • Expert Insight: BI 425809
                        • Expectations for Launch and Sales Opportunity of BI 425809 in Schizophrenia
                        • Likely Uses of BI 425809 for the Treatment of Schizophrenia
                      • Early-Phase Pipeline Analysis
                        • Select Compounds in Early-Phase Development for Schizophrenia
                    • Access & Reimbursement Overview
                      • Region-Specific Reimbursement Practices
                        • Key Market Access Considerations in Schizophrenia: United States
                        • General Reimbursement Environment: United States
                        • Key Market Access Considerations in Schizophrenia: EU5
                        • General Reimbursement Environment: EU5
                        • Key Market Access Considerations in Schizophrenia: Japan
                        • General Reimbursement Environment: Japan
                    • Appendix
                      • Schizophrenia Bibliography

                  launch Related Market Assessment Reports